PharmaTimes takes a look at GSK and Google’s joint effort into bioelectronic medicines:
GlaxoSmithKline is teaming up with Google’s parent company Alphabet to create a new company focused on developing bioelectronic medicines.
The UK drugs giant is setting up a joint venture – Galvani Bioelectronics – with Alphabet division Verily Life Sciences to enable research, development and commercialisation of new products in this relatively new field, which involves the use of miniaturised, implantable devices to modify electrical signals that might help tackle chronic diseases.
Each of its parent companies will contribute existing intellectual property rights and an investment of up to £540 million over seven years, subject to successful completion of various discovery and development milestones, giving GSK a 55 percent stake and Verily a 45 percent share in the business.
Galvani will be headquartered in the UK at GSK’s global R&D centre at Stevenage, with a second research hub at Verily’s facilities in South San Francisco, and the firm will initially take on around 30 expert scientists, engineers and clinicians, as well as stream funds into a broad range of collaborations with both parent companies, academia and other R&D organisations.
Initial work will centre on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type II diabetes, where substantial evidence already exists in animal models; and developing associated miniaturised, precision devices.
“This agreement with Verily to establish Galvani Bioelectronics signals a crucial step forward in GSK’s bioelectronics journey, bringing together health and tech to realise a shared vision of miniaturised, precision electrical therapies,” noted Moncef Slaoui, GSK’s Chairman of Global Vaccines. “Together, we can rapidly accelerate the pace of progress in this exciting field, to develop innovative medicines that truly speak the electrical language of the body.”
Kris Famm, GSK’s vice president of Bioelectronics R&D, will lead the new company.
Follow Us
Share
More News
IgniteData secures £1/2 million Innovate UK grant for ground-breaking clinical trial data project
How EHR-to-EDC technology is sparking better collaboration in clinical trials
6 Common Data Challenges For Clinical Researchers
How to choose an EHR-to-EDC solution
Leading healthcare technology expert Steve Tolle joins IgniteData
Guest blog: Joseph Lengfellner on the challenges and solutions for clinical trials – Part 2
Guest blog: Joseph Lengfellner on the challenges and solutions for clinical trials – Part 1
How structured data is used in clinical trials
Evidence from Electronic Health Records-to-Electronic Data Capture live pilot study
IgniteData and Leading New York City Cancer Center Collaborate to Solve the Clinical Trial Data Transfer Challenge
Clinical trial data mapping explained: Mapping EHR data
Quality data and the EHR-to-EDC dream – where and why we need to focus our energies
UK clinical trials landscape: 4 big influencers
ZS’s Qin Ye on trends and driving innovation in life sciences
Meet Archer, the platform transforming EHR-to-EDC data automation